Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520025 | 0.87 | HPGD (0.58) | KMT2AALDH1A1CRHBPCRHR2METAP1 | |
| SCHEMBL22409629 | 0.81 | APP (0.58) | KMT2AALDH1A1L3MBTL1HSD17B10MAPT | |
| SCHEMBL23388525 | 0.81 | APP (0.58) | KMT2AALDH1A1L3MBTL1HSD17B10MAPT | |
| SCHEMBL17199432 | 0.80 | ALDH1A1 (0.67) | KMT2AALDH1A1CRHBPCRHR2L3MBTL1 | |
| SCHEMBL4980344 | 0.80 | ALDH1A1 (0.54) | KMT2AALDH1A1CRHBPCRHR2 | |
| SCHEMBL15256496 | 0.80 | PIM1 (0.55) | KMT2AALDH1A1CRHBPCRHR2L3MBTL1 | |
| SCHEMBL1587773 | 0.80 | ALDH1A1 (0.66) | KMT2AALDH1A1CRHBPCRHR2 | |
| SCHEMBL9197946 | 0.79 | KMT2A (1.00) | KMT2AALDH1A1CRHBPCRHR2L3MBTL1 | |
| SCHEMBL12345520 | 0.79 | ALDH1A1 (0.65) | KMT2AALDH1A1CRHBPCRHR2L3MBTL1 | |
| SCHEMBL2074007 | 0.79 | ALDH1A1 (0.65) | KMT2AALDH1A1CRHBPCRHR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161823-B2 | Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2021-11-02 | — | — | US | disclosed |
| CN-111848637-B | Method for synthesizing cis/trans spiro compound containing oxygen nitrogen heteroatom | 扬州大学 | 2021-07-20 | — | — | CN | disclosed |
| CN-111848637-A | Method for synthesizing cis/trans spiro compound containing oxygen nitrogen heteroatom | 扬州大学 | 2020-10-30 | — | — | CN | disclosed |
| US-20200290975-A1 | ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2020-09-17 | — | — | US | disclosed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2885286-A1 | 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026997-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-20 | — | — | WO | disclosed |
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161823-B2 | Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof | PDK1, PDHA1, PDHA2 | KMT2A 1048/4885ALDH1A1 7/4885CRHBP 3904/4885 |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | KMT2A 2019/4885ALDH1A1 2507/4885CRHBP 4732/4885 |
| US-20200290975-A1 | ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF | PDK1, PDHA1, PDHA2 | KMT2A 1048/4885ALDH1A1 7/4885CRHBP 3904/4885 |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BRD4, BET1, BRDT | KMT2A 108/4885ALDH1A1 3159/4885CRHBP 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.